Next Article in Journal
Deep Dyspareunia One Year After Nerve-Sparing Endometriosis Surgery: An Observational Study Highlighting Undesirable Outcomes
Previous Article in Journal
Preventing Early Complications Following Oncologic Breast Surgery: The NDoCaSco Score for Targeted Negative-Pressure Wound Dressing
Previous Article in Special Issue
Interindividual Variability in Thyroid Cartilage Lamina Width and Its Implications for Personalized Medialization Thyroplasty
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Genomic and Epigenomic Advances in Hearing Loss: Molecular Mechanisms, Diagnostics, and Emerging Therapies

1
Unit of Otorhinolaryngology, Department of Adult and Development Age Human Pathology “Gaetano Barresi”, University of Messina, 98122 Messina, Italy
2
Department of Medicine and Surgery, University of Enna Kore, 94100 Enna, Italy
3
Ospedale Gravina Caltagirone Asp 3 Catania, 95123 Catania, Italy
4
Division of Laryngology and Broncho-Esophagology, Department of Otolaryngology-Head Neck Surgery, EpiCURA Hospital, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), 7000 Mons, Belgium
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2026, 16(6), 306; https://doi.org/10.3390/jpm16060306
Submission received: 11 March 2026 / Revised: 21 May 2026 / Accepted: 2 June 2026 / Published: 4 June 2026
(This article belongs to the Special Issue Personalized Diagnostics and Therapeutics in Otolaryngology)

Abstract

Background: Hearing loss is a widespread sensory disorder affecting over 1.5 billion people worldwide, with the number projected to exceed 700 million by 2050. It imposes social and economic burdens across all ages and regions. Approximately half of adult cases are preventable, but the underlying causes are complex, with 75–80% due to autosomal recessive genetic factors and key roles for mutations in genes such as GJB2. Advances in sequencing technologies have accelerated gene discovery, but challenges remain in interpreting variants. Epigenetic mechanisms such as DNA methylation and histone modifications are increasingly recognized as crucial in auditory biology and could offer new biomarkers and therapeutic targets. Integrating epidemiological, genetic, and epigenomic data is essential to developing targeted prevention and treatment strategies to reduce the global burden of hearing loss. Methods: This narrative review examines recent genomic and epigenomic advances in hearing loss, with particular emphasis on molecular mechanisms, emerging diagnostic applications, and translational therapeutic opportunities. A comprehensive review of current epidemiological data, genetic studies, and epigenomic research was conducted using the peer-reviewed literature from international databases. Key areas of interest include inheritance patterns, molecular pathways, and recent advances in omics technologies. Results: Epigenetic mechanisms, including DNA methylation and histone modifications, are increasingly recognized as important regulators of cochlear development and hair cell survival, although much of the current evidence remains preclinical. Studies suggest that peripheral epigenetic signatures may serve as biomarkers for early diagnosis and risk stratification. Conclusions: Integrating established screening pathways with epidemiological trends and molecular knowledge offers a promising path toward precision medicine in hearing care. Connecting these domains is essential to developing equitable and effective interventions and addressing persistent global disparities in hearing health. This review highlights the evolving landscape of auditory genetics and epigenetics and outlines future directions for translational research and personalized therapy.
Keywords: hearing loss; epigenetic mechanisms; DNA methylation; histone modifications; prevention; treatment strategies; hearing health; translational research hearing loss; epigenetic mechanisms; DNA methylation; histone modifications; prevention; treatment strategies; hearing health; translational research

Share and Cite

MDPI and ACS Style

Alberti, G.; Galletti, F.; Portelli, D.; Galletti, C.; Loteta, S.; Galletti, B.; Lentini, M.; Ronsivalle, S.; Maira, S.; Lechien, J.R.; et al. Genomic and Epigenomic Advances in Hearing Loss: Molecular Mechanisms, Diagnostics, and Emerging Therapies. J. Pers. Med. 2026, 16, 306. https://doi.org/10.3390/jpm16060306

AMA Style

Alberti G, Galletti F, Portelli D, Galletti C, Loteta S, Galletti B, Lentini M, Ronsivalle S, Maira S, Lechien JR, et al. Genomic and Epigenomic Advances in Hearing Loss: Molecular Mechanisms, Diagnostics, and Emerging Therapies. Journal of Personalized Medicine. 2026; 16(6):306. https://doi.org/10.3390/jpm16060306

Chicago/Turabian Style

Alberti, Giuseppe, Francesco Galletti, Daniele Portelli, Cosimo Galletti, Sabrina Loteta, Bruno Galletti, Mario Lentini, Salvatore Ronsivalle, Salvatore Maira, Jerome Rene Lechien, and et al. 2026. "Genomic and Epigenomic Advances in Hearing Loss: Molecular Mechanisms, Diagnostics, and Emerging Therapies" Journal of Personalized Medicine 16, no. 6: 306. https://doi.org/10.3390/jpm16060306

APA Style

Alberti, G., Galletti, F., Portelli, D., Galletti, C., Loteta, S., Galletti, B., Lentini, M., Ronsivalle, S., Maira, S., Lechien, J. R., Mat, Q., & Maniaci, A. (2026). Genomic and Epigenomic Advances in Hearing Loss: Molecular Mechanisms, Diagnostics, and Emerging Therapies. Journal of Personalized Medicine, 16(6), 306. https://doi.org/10.3390/jpm16060306

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop